All That Glitters Is Not Gold: Issues and Risks Around GLP-1 Medications The effectiveness of GLP-1 medications in promoting weight loss has led to a surge in off-label demand, particularly for cosmetic purposes
Introduction : Cardiovascular disease (CVD) remains a leading cause of mortality worldwide, emphasizing the need for effective prevention and management strategies
Unlike some compounded regimens that allow for flexible or micro-dosed schedules, FDA-approved GLP-1s have specific dosing timelines (usually weekly)
Notably, the median PA time of ~6 days (for cases needing extra review) means many patients wait well over a week to start treatment ( [5] )
After six months I was really depressed
What the Phase 2 Data Shows The retatrutide Phase 2 obesity trial (Jastreboff et al., New England Journal of Medicine , 2023) is the primary published source for quantifying the heart rate effect